Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
View original at globenewswire.comPress Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing thr…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
The totality of data reinforce confidence in amlitelimab's potential to deliver both Q12W dosing from the start and progressive efficacy through Week 52
80% confidenceAmlitelimab efficacy progressively increases throughout the treatment period with some patients improving as early as Week 2
80% confidenceThese results validate amlitelimab's novel mechanism of action to block OX40-ligand without T-cell depletion and its promise to normalize the immune system over time
80% confidenceAmlitelimab was well-tolerated and the safety profile was consistent with previously reported data in SHORE and COAST 2 studies
80% confidence